{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:21:36Z","timestamp":1784233296257,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Emerging research indicates the potential for early transition from intravenous to oral antimicrobial therapy in certain infections. This trend may have implications for outpatient parenteral antibiotic therapy (OPAT) programs, as the demand for prolonged intravenous treatment could decrease. The objective of this study was to evaluate the frequency and evolution of OPAT courses of\u2009\u2265\u200914\u00a0days over the years and determine the medical justification for those prolonged treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All patients treated intravenously for\u2009\u2265\u200914\u00a0days by the OPAT program at Lausanne University Hospital, Switzerland, between 2017 and 2022 were included in the study. Data were extracted from a prospectively established OPAT database. Prevalence of prolonged antibiotic treatment and its clinical and microbiological information were identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>During the study period, a total of 2,448 treatment courses were administered: 1,636 intravenous (IV) and 812 oral treatments. Of the IV treatments courses, 749 (36%) were of a duration of\u2009\u2265\u200914\u00a0days, without discernible trend over the 6-year study period. The most common type of infections needing prolonged treatment were bone and joint infections (31%), endovascular infections (18%), complicated intra-abdominal infections (15%), and urinary tract infections (11%), with only minor fluctuations in these proportions during the study period. Finally, the use of second-line antibiotics (piperacillin-tazobactam, carbapenems and vancomycin) did not increase over the years, suggesting that prolonged intravenous antibiotic therapy is not linked to an increase of anti-microbial resistance in our cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Despite the general trend towards shorter intravenous treatment courses in infectious diseases, our OPAT unit did not observe a decline in the use of prolonged intravenous antibiotic therapy between 2017 and 2022, suggesting that OPAT units will probably not see a decrease in their activities in the near future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-024-10170-0","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:04:26Z","timestamp":1730970266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolonged outpatient parenteral antimicrobial treatment: frequency and evolution over a six-year period in a Swiss University Hospital"],"prefix":"10.1186","volume":"24","author":[{"given":"Aline","family":"Munting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyne","family":"Arensdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"de Valli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"5","key":"10170_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/jac\/dks003","volume":"67","author":"ALN Chapman","year":"2012","unstructured":"Chapman ALN, Seaton RA, Cooper MA, Hedderwick S, Goodall V, Reed C, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother. 2012;67(5):1053\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10170_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciy867","volume":"68","author":"AH Norris","year":"2019","unstructured":"Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clinical infectious diseases\u202f: an official publication of the Infectious Diseases Society of America. 2019;68(1):1\u20134.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"10170_CR3","doi-asserted-by":"publisher","first-page":"dlae111","DOI":"10.1093\/jacamr\/dlae111","volume":"6","author":"P Reidy","year":"2024","unstructured":"Reidy P, Breslin T, Muldoon E. Outpatient parenteral antimicrobial therapy (OPAT) across the world: a comparative analysis-what lessons can we learn? JAC Antimicrob Resist. 2024;6(4):dlae111.","journal-title":"JAC Antimicrob Resist."},{"issue":"5","key":"10170_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019;380(5):415\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"10170_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019;380(5):425\u201336.","journal-title":"N Engl J Med"},{"issue":"2","key":"10170_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jac\/dkh088","volume":"53","author":"M Wilcox","year":"2004","unstructured":"Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004;53(2):335\u201344.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10170_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203\u201312.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10170_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1086\/424506","volume":"39","author":"J Schrenzel","year":"2004","unstructured":"Schrenzel J, Harbarth S, Schockmel G, Genn\u00e9 D, Bregenzer T, Flueckiger U, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clinical infectious diseases\u202f: an official publication of the Infectious Diseases Society of America. 2004;39(9):1285\u201392.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"15","key":"10170_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435\u201386.","journal-title":"Circulation"},{"issue":"2","key":"10170_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/dkr450","volume":"67","author":"FK Gould","year":"2012","unstructured":"Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269\u201389.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10170_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","volume":"180","author":"B Spellberg","year":"2020","unstructured":"Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. JAMA Intern Med. 2020;180(5):769\u201377.","journal-title":"JAMA Intern Med"},{"issue":"39","key":"10170_CR12","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"V Delgado","year":"2023","unstructured":"Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948\u20134042.","journal-title":"Eur Heart J."},{"issue":"7","key":"10170_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/cid\/civ436","volume":"61","author":"ML Grayson","year":"2015","unstructured":"Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, et al. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. Clin Infect Dis. 2015;61(7):1141\u20133.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10170_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/jac\/dkz015","volume":"74","author":"I Karaiskos","year":"2019","unstructured":"Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D, et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019;74(5):1430\u20137.","journal-title":"J Antimicrob Chemother"}],"updated-by":[{"DOI":"10.1186\/s12879-025-11041-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10170-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T12:29:51Z","timestamp":1746448191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10170"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10170-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12879-025-11041-y","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-025-11041-y","URL":"https:\/\/doi.org\/10.1186\/s12879-025-11041-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Ethics Committee of the Canton of Vaud, Switzerland (protocol ID 34\/14). All patients provided informed consent to participate in the registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1255"}}